GC
RPRX icon

Guggenheim Capital’s Royalty Pharma RPRX Stock Holding History

Guggenheim Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,197
Closed -$1.91M – 1657
2025
Q1 		$1.91M Sell
61,197
-11,884
-16% -$377K 0.02% 654
2024
Q4 		$1.86M Sell
73,081
-82,768
-53% -$2.19M 0.02% 676
2024
Q3 		$4.41M Buy
155,849
+4,864
+3% +$135K 0.03% 572
2024
Q2 		$3.98M Buy
150,985
+27,296
+22% +$757K 0.03% 588
2024
Q1 		$3.76M Buy
123,689
+22,139
+22% +$653K 0.03% 658
2023
Q4 		$2.85M Sell
101,550
-30,879
-23% -$849K 0.02% 716
2023
Q3 		$3.59M Buy
132,429
+21,220
+19% +$630K 0.03% 606
2023
Q2 		$3.42M Buy
111,209
+355
+0.3% +$12K 0.03% 660
2023
Q1 		$3.99M Sell
110,854
-15,761
-12% -$584K 0.03% 606
2022
Q4 		$5M Buy
126,615
+30,977
+32% +$1.29M 0.04% 528
2022
Q3 		$3.84M Sell
95,638
-25,420
-21% -$1.09M 0.04% 597
2022
Q2 		$5.09M Sell
121,058
-9,874
-8% -$405K 0.04% 533
2022
Q1 		$5.1M Sell
130,932
-13,733
-9% -$539K 0.03% 644
2021
Q4 		$5.76M Buy
144,665
+25,476
+21% +$990K 0.03% 632
2021
Q3 		$4.31M Buy
119,189
+110,123
+1,215% +$4.28M 0.03% 723
2021
Q2 		$372K Buy
+9,066
New +$386K ﹤0.01% 1940

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Guggenheim Capital's RPRX Position: Q2 2025 in Review

Guggenheim Capital sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 61,197 shares — an estimated $1.91M sold.

Guggenheim Capital first reported a position in RPRX in Q2 2021 and held it in 16 quarters. The position peaked at $5.76M in Q4 2021. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Guggenheim Capital reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Guggenheim Capital sold 61,197 Royalty Pharma shares in Q2 2025, an estimated $1.91M.
  • Guggenheim Capital first reported a position in Royalty Pharma in Q2 2021 and held it in 16 quarters.
  • Guggenheim Capital's Royalty Pharma position peaked at $5.76M in Q4 2021.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Guggenheim Capital's 13F filing for Q2 2025, filed 13 Aug 2025.